BRNS
Barinthus Biotherapeutics
BRNS
BRNS
16 hedge funds and large institutions have $29.5M invested in Barinthus Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
1
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$46K |
| 2 |
Morgan Stanley
New York
|
+$17.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$185 |
Top Sellers
| 1 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$276K |
| 2 |
Renaissance Technologies
New York
|
-$38.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$30.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.79K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$68 |
